Cardio, Incorporated

Regenerative medicine for cardio-vascular disorders, cellular therapy, gene therapy and development of tissue-engineering-based therapies.

Cardio Inc. was established in 2001 as a campus venture of Osaka University Graduate School of Medicine (founder: Yoshiki Sawa). Their core business is the development of treatment and medical devices in the field of cardiovascular diseases using regenerative medicine and tissue engineering. Main research partners of Cardio, Inc. are the Osaka University Graduate School of Medicine, the Kyoto University Graduate School of Medicine, the Chiba University Graduate School of Medicine, the Kanazawa University Graduate School of Medical Science and the Foundation for Biomedical Research and Innovation in Kobe. Current partners are Asahi Intecc Co., LTD and MERA (Man- Environment Relations Association).

Koji Yoshida, President, CEO

4-15-5, Temma, Kita-ku
Osaka 530-0043
Japan
Phone: +81-6353-7347
Fax: +81-6353-7348

The company`s aim is to improve the cardiac function by transplanting cells and tissues, injecting drugs and inducing myocardial regeneration. The establishment of various cell transplantation techniques for cardiac regenerative medicine are in process. The company provides the following novel technologies to collaborations and companies: Drug Discovery: searching a master gene of cardiac muscle and researching into cells for transplantation; curative medicine for heart diseases using a protein of low molecular weight to induce effective genes in myocardial protection in order to prevent myocardial infarctions; cytikine and peptide preperations for angiogenic therapy; diagnostic reagents based on proteomics. Devices for regenerative medicine: cell sheet: treatment of heart failures, MI (myocardial infarction) and DCM (dilated cardiomyopathy); cell injection catheter system: treatment for slight or medium heart failure and localised MI Devices utilising in situ tissue engineering: decellularised tissue for implanted medical devices; biodegradable polymers in auto-regenerative cardiovascular repair patches; nanotechnology: myocardial regenerative sheets.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.